TrialBlood2007

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Madeleine Duvic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.